Background Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder lacking a gold-standard diagnostic ...
Adenosine deaminase 2 deficiency (DADA2) is an inborn error of immunity leading to systemic vasculitis, haematological manifestations, immune deficiency and/or autoimmunity. We report the case of a 26 ...
Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in ...
Objectives Treatment of rheumatoid arthritis (RA) relies on immunomodulatory drugs that can compromise immunity, inducing secondary immunodeficiency (SID). However, features of SID, such as ...
Objective Sarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)—driven in part by chronic inflammation—and is ...
Introduction Inflammatory myopathies (IM) are a group of severe autoimmune diseases, sharing some similarities, whose cause is unknown and treatment is empirical. While C-protein-induced myositis (CIM ...
Corticosteroid-induced osteoporosis is the most common form of secondary osteoporosis and the first cause in young people. Bone loss and increased rate of fractures occur early after the initiation of ...
Background Although genome-wide association studies (GWASs) have identified more than 100 loci associated with rheumatoid arthritis (RA) susceptibility, the causal genes and biological mechanisms ...
Background Salivary gland dysfunction in Sjögren’s disease (SjD) is clinically heterogeneous. Unstimulated whole salivary flow (UWSF) reflects basal secretion, while stimulated tests such as the Saxon ...
Objectives Eosinophilic granulomatosis with polyangiitis (EGPA) is classified as a subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). A recent genome-wide association ...
Objective To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results